Evidence map›Paper›PMID 29497927›Full record

ReviewCurrent osteoporosis reports2018

Recent Advances in Understanding Bisphosphonate Effects on Bone Mechanical Properties.

Matthew R Allen

Abstract readReview
In one paragraph

Review in Current osteoporosis reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Suppression of Remodeling and Bone Fragility.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2023
    Article
  7. Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Matthew R AllenDepartments of Anatomy and Cell Biology, Medicine-Nephrology and Orthopaedic Surgery, Indiana University School of Medicine, 635 Barnhill Dr., MS 5035, Indianapolis, IN, 46202, USA. matallen@iupui.edu.
Indiana University School of Medicine

Funding

Enhancing bone strength using combination drug therapyR01AR062002 · NIAMS · INDIANA UNIVERSITY INDIANAPOLIS · PI ALLEN, MATTHEW R · 2012 to 2016
$2.4M
Pathogenesis of compromised bone quality and mechanics in chronic kidney disease.R01DK110871 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI ALLEN, MATTHEW R, MOE, SHARON M · 2016 to 2019
$1.8M
Treating bone deterioration associated with chronic kidney diseaseI01BX003025 · VA · RLR VA MEDICAL CENTER · PI ALLEN, MATTHEW R · 2016 to 2024
–
BLRD VA I01 BX003025NIAMS NIH HHS R01 AR062002NIDDK NIH HHS R01 DK110871
6 · The paper itself

Abstract

purpose of the reviewBisphosphonates have well-established effects on suppressing bone resorption and slowing bone loss, yet the effects on bone mechanical properties are less clear. We review recent data from pre-clinical and clinical experiments that assessed mechanical properties of bisphosphonate-treated specimens. RECENT

findingsPre-clinical work has utilized new techniques to show reduced fatigue life and transfer of stress from the mineral to collagen. Several notable studies have examined mechanical properties of tissue from patients treated with bisphosphonates with mixed results. Pre-clinical data suggest effects on mechanics may be independent of remodeling suppression. The direct effect of bisphosphonates on bone mechanics remains unclear but recent work has set a solid foundation for the coming years.

Indexed as

Biomechanical PhenomenaBone and BonesBone Density Conservation AgentsBone RemodelingDiphosphonatesFractures, BoneHumansStress, MechanicalBone Density Conservation AgentsDiphosphonatesAnti-remodelingAtypical fractureBiomechanicsRemodeling suppressionZoledronate

Identifiers

PMID29497927
PMCPMC6263169
OpenAlexW2790859839

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.